Working… Menu

Atorvastatin in Management of Newly Diagnosed ITP

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03692754
Recruitment Status : Recruiting
First Posted : October 2, 2018
Last Update Posted : March 23, 2020
Information provided by (Responsible Party):
Ming Hou, Shandong University

Brief Summary:
The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of atorvastatin for the treatment of adults with immune thrombocytopenia (ITP).

Condition or disease Intervention/treatment Phase
Immune Thrombocytopenia Purpura, Thrombocytopenic Drug: Atorvastatin 20mg Drug: Atorvastatin 10mg Phase 4

Detailed Description:
The investigators anticipate to undertaking a parallel group, single-centre, randomised controlled trial of 30 ITP adult patients, which have no indications of glucocorticoid therapy (platelets count > 30*10^9/L )from Qilu Hospital of Shandong University in China.15 of the participants are randomly selected to receive atorvastatin in 20 mg/d combining with 10 mg/d for 6 months. Platelet count, bleeding and other symptoms were evaluated before and after treatment, adverse events are also recorded throughout the study in order to report the efficacy and safety of atorvastatin for the treatment of adults with ITP.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-center Prospective Randomized Study of Atorvastatin in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP)
Actual Study Start Date : March 1, 2020
Estimated Primary Completion Date : December 1, 2021
Estimated Study Completion Date : December 1, 2022

Arm Intervention/treatment
Active Comparator: AT with 10 mg/d
The patients will be given receive atorvastatin in 10 mg/d
Drug: Atorvastatin 10mg
Atorvastatin will be given in 10 mg po qn for 1 year
Other Name: atorvastatin calcium

Active Comparator: AT with 20 mg/d
The patients will be given receive atorvastatin in 20 mg/d
Drug: Atorvastatin 20mg
Atorvastatin will be given in 20 mg po qn for 1 year
Other Name: atorvastatin calcium

Primary Outcome Measures :
  1. Evaluation of platelet response [ Time Frame: up to 1 year per subject ]
    Platelet count will be observed at 1 month, 3 months, 6 months and 12 months after atorvastatin therapy

Secondary Outcome Measures :
  1. Therapy associated adverse events [ Time Frame: up to 1 year per subject ]
    The number and frequency of therapy associated adverse events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Meet the diagnostic criteria for immune thrombocytopenia.
  2. within 3 months from diagnosis,untreated patients, may be male orfemale, between the ages of 18 ~ 80 years.
  3. To show a platelet count > 30×10^9/L and without bleeding manifestations.

Exclusion Criteria:

  1. Received chemotherapy or anticoagulants or other drugs affecting theplatelet counts within 3 months before the screening visit.
  2. Received steroids or other effective therapy for immune thrombocytopenia.
  3. Current HIV infection or hepatitis B virus or hepatitis C virus infections.
  4. Severe medical condition (lung, hepatic or renal disorder) other than ITP.
  5. Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia)
  6. Female patients who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period.
  7. Have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test.
  8. Patients who are deemed unsuitable for the study by the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03692754

Layout table for location contacts
Contact: Ming Hou, Dr +86-531-82169114 ext 9879

Layout table for location information
China, Shandong
Qilu hospital, Shandong University Recruiting
Jinan, Shandong, China, 250012
Contact: Ming Hou   
Principal Investigator: Ming Hou         
Sponsors and Collaborators
Shandong University
Layout table for investigator information
Principal Investigator: Ming Hou, Dr Shandong University
Layout table for additonal information
Responsible Party: Ming Hou, Professor and Director, Shandong University Identifier: NCT03692754    
Other Study ID Numbers: Atorvastatin in ITP
First Posted: October 2, 2018    Key Record Dates
Last Update Posted: March 23, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ming Hou, Shandong University:
Immune Thrombocytopenia
Additional relevant MeSH terms:
Layout table for MeSH terms
Immune System Diseases
Purpura, Thrombocytopenic, Idiopathic
Purpura, Thrombocytopenic
Blood Platelet Disorders
Hematologic Diseases
Blood Coagulation Disorders
Pathologic Processes
Skin Manifestations
Thrombotic Microangiopathies
Hemorrhagic Disorders
Autoimmune Diseases
Calcium, Dietary
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Bone Density Conservation Agents
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors